Report Projects Costs for CAR T-Cell Therapies

A study published in JAMA Oncology assessed overall costs for the two U.S. Food and Drug Administration-approved chimeric antigen receptor (CAR) T-cell therapies, taking into costs outside of the drug list price.

The list price for tisagenlecleucel is $475,000 and $373,000 for axicabtagene ciloleucel at; however, these prices do not account for costs associated with leukapheresis, lymphodepletion therapy, and adverse events.

The researchers estimate that the true costs are $510,963 for tisagenlecleucel and $402,647 for axicabtagene ciloleucel. The mean additional non-product costs are about $30,000 to $35,000, which represents 7% of the total cost.

Source: JAMA Oncology